MX2023005068A - Variantes de interleucina-18 y métodos de uso. - Google Patents
Variantes de interleucina-18 y métodos de uso.Info
- Publication number
- MX2023005068A MX2023005068A MX2023005068A MX2023005068A MX2023005068A MX 2023005068 A MX2023005068 A MX 2023005068A MX 2023005068 A MX2023005068 A MX 2023005068A MX 2023005068 A MX2023005068 A MX 2023005068A MX 2023005068 A MX2023005068 A MX 2023005068A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- interleukin
- variants
- stabilized
- polypeptides
- Prior art date
Links
- 102000003810 Interleukin-18 Human genes 0.000 title abstract 4
- 108090000171 Interleukin-18 Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 101710205006 Interleukin-18-binding protein Proteins 0.000 abstract 1
- 102100035017 Interleukin-18-binding protein Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000007781 signaling event Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción proporciona composiciones y métodos que comprenden polipéptidos de IL-18 estabilizados par uso en aplicaciones terapéuticas y no terapéuticas. En algunos casos, las proteínas IL-18 estabilizadas proporcionan actividad de señalización IL-18 aún en presencia de una molécula inhibidora tal como IL-18BP. También se proporcionan métodos de administración y métodos para fabricar polipéptidos activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108794P | 2020-11-02 | 2020-11-02 | |
| PCT/US2021/057741 WO2022094473A1 (en) | 2020-11-02 | 2021-11-02 | Interleukin-18 variants and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005068A true MX2023005068A (es) | 2023-07-14 |
Family
ID=81384408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005068A MX2023005068A (es) | 2020-11-02 | 2021-11-02 | Variantes de interleucina-18 y métodos de uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11850276B2 (es) |
| EP (1) | EP4236990A1 (es) |
| JP (1) | JP2023550545A (es) |
| KR (1) | KR20230117120A (es) |
| CN (1) | CN116723851A (es) |
| AR (1) | AR123978A1 (es) |
| AU (1) | AU2021371040A1 (es) |
| CA (1) | CA3197145A1 (es) |
| GB (1) | GB2617483A (es) |
| IL (1) | IL302517A (es) |
| MX (1) | MX2023005068A (es) |
| TW (1) | TW202233657A (es) |
| WO (1) | WO2022094473A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230146665A1 (en) | 2021-07-27 | 2023-05-11 | Xencor, Inc. | Il-18-fc fusion proteins |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| WO2024044780A1 (en) * | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
| WO2024051728A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Il-18 variant polypeptides |
| US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| EP0816499A3 (en) | 1996-06-27 | 1999-10-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| JP3955352B2 (ja) | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| TWI227136B (en) | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| NZ523123A (en) | 2000-06-02 | 2005-12-23 | Smithkline Beecham Corp | Methods of treating viral diseases with IL-18 and IL-18 combinations with anti-viral drugs |
| SI1392830T1 (sl) | 2001-03-08 | 2006-06-30 | Ares Trading Sa | Mutanti interlevkina-18, njihova proizvodnja in uporaba |
| ATE459647T1 (de) * | 2003-04-15 | 2010-03-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| EP3536333B1 (en) * | 2010-01-04 | 2022-08-03 | Mapi Pharma Limited | Depot system comprising glatiramer acetate |
| WO2017102010A1 (en) | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CN111315395A (zh) * | 2017-09-06 | 2020-06-19 | 耶鲁大学 | 白细胞介素-18变体和使用方法 |
| US20210015891A1 (en) * | 2019-05-13 | 2021-01-21 | Simcha IL-18, Inc. | Interleukin-18 mimics and methods of use |
-
2021
- 2021-11-02 WO PCT/US2021/057741 patent/WO2022094473A1/en active Application Filing
- 2021-11-02 KR KR1020237018440A patent/KR20230117120A/ko unknown
- 2021-11-02 TW TW110140842A patent/TW202233657A/zh unknown
- 2021-11-02 JP JP2023551948A patent/JP2023550545A/ja active Pending
- 2021-11-02 MX MX2023005068A patent/MX2023005068A/es unknown
- 2021-11-02 AU AU2021371040A patent/AU2021371040A1/en active Pending
- 2021-11-02 CA CA3197145A patent/CA3197145A1/en active Pending
- 2021-11-02 IL IL302517A patent/IL302517A/en unknown
- 2021-11-02 CN CN202180089105.7A patent/CN116723851A/zh active Pending
- 2021-11-02 AR ARP210103038A patent/AR123978A1/es unknown
- 2021-11-02 EP EP21887776.9A patent/EP4236990A1/en active Pending
- 2021-11-02 GB GB2308183.9A patent/GB2617483A/en active Pending
-
2022
- 2022-12-01 US US18/060,816 patent/US11850276B2/en active Active
-
2023
- 2023-11-03 US US18/501,206 patent/US20240075104A1/en active Pending
- 2023-11-03 US US18/501,210 patent/US20240066100A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022094473A1 (en) | 2022-05-05 |
| GB2617483A (en) | 2023-10-11 |
| US20240066100A1 (en) | 2024-02-29 |
| AU2021371040A1 (en) | 2023-06-22 |
| US20240075104A1 (en) | 2024-03-07 |
| US20230277625A1 (en) | 2023-09-07 |
| IL302517A (en) | 2023-07-01 |
| KR20230117120A (ko) | 2023-08-07 |
| CA3197145A1 (en) | 2022-05-05 |
| TW202233657A (zh) | 2022-09-01 |
| GB202308183D0 (en) | 2023-07-19 |
| AR123978A1 (es) | 2023-02-01 |
| EP4236990A1 (en) | 2023-09-06 |
| CN116723851A (zh) | 2023-09-08 |
| JP2023550545A (ja) | 2023-12-01 |
| US11850276B2 (en) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005068A (es) | Variantes de interleucina-18 y métodos de uso. | |
| MX2020002542A (es) | Variantes de interleucina-18 y metodos de uso. | |
| NZ761434A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| NO20055838D0 (no) | Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav | |
| TW200607816A (en) | Metastin derivatives and use thereof | |
| HRP20050024A2 (en) | Pegylated t20 polypeptide | |
| BRPI0517015A (pt) | compostos e composições como inibidores de atividade de receptor 1 de canabinóide | |
| WO2007110231A3 (en) | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES | |
| MY162324A (en) | Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections | |
| WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
| TW200407425A (en) | Human coagulation factor VII polypeptides | |
| MX2019004487A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
| JOP20220071A1 (ar) | سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra | |
| MX2021004598A (es) | Inhibidores selectivos de rgmc y el uso de los mismos. | |
| MX2021000322A (es) | Enzimas de variante fosfopentomutasa modificada geneticamente. | |
| WO2011069037A3 (en) | Stabilization and storage of biological pharmaceutical compositions | |
| MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2021015761A (es) | Polipeptidos. | |
| MX2021011596A (es) | Compuestos y composiciones como moduladores de se?alizacion tlr. | |
| MX2021007552A (es) | Variantes de alfa-galactosidasa humana. | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. |